Adrenal Cortical Extract Taken Off Drug Market | U.S. GAO

Lapse in Appropriations

Please note that a lapse in appropriations has caused GAO to shut down its operations. Therefore, GAO will not be able to publish reports or otherwise update this website until GAO resumes operations. In addition, the vast majority of GAO personnel are not permitted to work. Consequently, calls or emails to agency personnel may not be returned until GAO resumes operations. For details on how the bid protest process will be handled during the shutdown, please see the legal decisions page. For information related to the GAO Personnel Appeals Board (PAB), please see the PAB webpage.

Highlights

Adrenal cortical extract (ACE) products were once recommended in the treatment of Addison's disease and for several other indications including hypoglycemia. In January 1978, the Food and Drug Administration (FDA) advised drug firms marketing ACE products that the drug represented a substantial risk of undertreatment because of its low potency and the resulting potential hazard to patients.

Full Report

Full Report (40 pages)

Media Inquiries

Sarah Kaczmarek

Managing Director

Office of Public Affairs

Public Inquiries

Topics

DiseasesDrugsFood and drug lawPharmaceutical industryPhysiciansProduct evaluationProduct recallsRegulatory agenciesTherapyPrescription drugs